The clinical trial study NCT02794883 reported the use of tremelimumab and durvalumab (MEDI4736), a new class of drug based on an antibody targeted the PD-1, for phase 2 glioblastoma treatment. This evidence concerns the gene PDCD1 and glioblastoma.